Our Board of Directors
Our board is comprised of years of leadership and professional experience; each is committed to our mission to raise awareness and funds in the fight against pediatric cancer.
NCI News Releases
04 December 2021
The latest cancer news from the U.S. government's principal agency for cancer research.-
Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy
A Children’s Oncology Group trial shows that the combination of all-trans retinoic acid and arsenic trioxide is highly effective in children with acute promyelocytic leukemia. The therapy avoids or minimizes the use of conventional chemotherapy.
-
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live. The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix.
-
Annual Report to the Nation Part 2: Patient economic burden of cancer care more than $21 billion in the United States in 2019
Part 2 of the 2021 Annual Report to the Nation on the Status of Cancer, finds that the patient economic burden associated with cancer care in the United States in 2019 was $21.09 billion. This includes patient out-of-pocket costs of $16.22 billion and patient time costs of $4.87 billion.
Feed not found.
